ReviewDrug design, development and therapy2011
Current and emerging drugs for the treatment of inflammatory bowel disease.
Review in Drug design, development and therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease.The Cochrane database of systematic reviews · 2020Pooled it
- Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view.World journal of gastroenterology · 2013Pooled it
- Chronotherapy in Inflammatory Bowel Disease: Biological Rationale, Human Evidence, and a Clinical Implementation Framework.Digestive diseases and sciences · 2026Review
- Review
- Detection of Calpain-Mediated Beclin-1 Cleavage for Drug Discovery in Inflammatory Bowel Diseases.Cells · 2026Article
- Predictors of First Anti-TNF Treatment Failure in Patients with Inflammatory Bowel Disease: A Single-Center Cohort Study.Biomedicines · 2026Article
- Astragaloside IV fromAntioxidants (Basel, Switzerland) · 2026Article
- Functional Evaluation of Computationally Designed IL-10 in IL-10 KO Mice.Biomolecules · 2026Article
- Strain-Specific microRNA Reprogramming of Human Dendritic Cells by Probiotic and CommensalMicroorganisms · 2026Article
- Treatment of Inflammatory Bowel Disease with Drugs Targeting PANoptosis: A Comprehensive Review.Biomedicines · 2026Review
- Cardiovascular disease: extraintestinal manifestation of inflammatory bowel disease.Intestinal research · 2025Review
- Nanotechnology-based Approaches for Targeted Drug Delivery to the Small Intestine: Advancements and Challenges.Current pharmaceutical design · 2025Review
- (-)-Fenchone Ameliorates TNBS-Induced Colitis in Rats via Antioxidant, Immunomodulatory, and Cytoprotective Mechanisms.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment.Inflammatory bowel diseases · 2024Article
- Change in systemic steroid use and surgery rate in patients with inflammatory bowel disease: a Japanese real-world database analysis.Journal of gastroenterology · 2024Article
- Red Cabbage Juice-Mediated Gut Microbiota Modulation Improves Intestinal Epithelial Homeostasis and Ameliorates Colitis.International journal of molecular sciences · 2023Article
- The Anti-Inflammatory Effect of a Probiotic Cocktail in Human Feces Induced-Mouse Model.Inflammation · 2023Article
- Plant-derived nanovesicles: harnessing nature's power for tissue protection and repair.Journal of nanobiotechnology · 2023Review
- Ellagic Acid Prevented Dextran-Sodium-Sulfate-Induced Colitis, Liver, and Brain Injury through Gut Microbiome Changes.Antioxidants (Basel, Switzerland) · 2023Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the last decade a large number of biological agents against tumor necrosis factor-α (TNF-α), as well as many biochemical substances and molecules specifically for the medical treatment of patients with inflammatory bowel disease (IBD), have been developed. This enormous progress was a consequence of the significant advances in biotechnology along with the increased knowledge of the underlying pathophysiological mechanisms involved in the pathogenesis of IBD. However, conventional therapies remain the cornerstone of treatment for most patients. During recent years conventional and biologic IBD therapies have been optimized. Newer mesalazine formulations with a reduced pill size and only one dose per day demonstrate similar efficacy to older formulations. New corticosteroids retain the efficacy of older corticosteroids while exhibiting a higher safety profile. The role of antibiotics and probiotics has been further clarified. Significant progress in understanding thiopurine metabolism has improved the effective dose along with adjunctive therapies. Quite a large number of substances and therapies, including biologic agents other than TNF-α inhibitors, unfractionated or low-molecular-weight heparin, omega-3 polyunsaturated fatty acids, microbes and microbial products, leukocytapheresis, and other substances under investigation, could offer important benefits to our patients. In this paper we review the established and emerging therapeutic strategies in patients with Crohn's disease and ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.